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Abstract 
Background: Real-world studies of the burden of severe haemophilia B in the context of recent therapeutic 
advances such as extended half-life (EHL) factor IX (FIX) products are limited. We analysed data from the recent CHESS 
II study to better understand the clinical, humanistic, and economic burden of severe haemophilia B in Europe. 
Data from male adults with severe haemophilia B receiving prophylaxis were analysed from the retrospective cross-
sectional CHESS II study conducted in Germany, France, Italy, Spain and the United Kingdom. Inhibitors were exclu-
sionary. Patients and physicians completed questionnaires on bleeding, joint status, quality of life, and haemophilia-
related direct and indirect costs (2019–2020). All outcomes were summarised using descriptive statistics.
Results: A total of 75 CHESS II patients were eligible and included; 40 patients (53%) provided self-reported out-
comes. Mean age was 36.2 years. Approximately half the patients were receiving EHL versus standard half-life (SHL) 
prophylaxis (44% vs 56%). Most patients reported mild or moderate chronic pain (76%) and had ≥ 2 bleeding events 
per year (70%), with a mean annualised bleed rate of 2.4. Mean annual total haemophilia-related direct medical cost 
per patient was €235,723, driven by FIX costs (€232,328 overall, n = 40; €186,528 for SHL, €290,620 for EHL). Mean 
annual indirect costs (€8,973) were driven by early retirement or work stoppage due to haemophilia. Mean quality of 
life (EQ-5D) score was 0.67.
Conclusions: These data document a substantial, persistent real-world burden of severe haemophilia B in Europe. 
Unmet needs persist for these patients, their caregivers, and society.
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Background
Haemophilia B is less prevalent than haemophilia A, 
with estimates of 3.8 and 17.1 cases per 100,000 males, 
respectively [1]. As such, the scientific literature tends to 
focus much more on burden and outcomes of patients 
with haemophilia A alone, or haemophilia at large (A and 
B, comprised mostly of patients with haemophilia A). 
However, patients with haemophilia B endure an ongo-
ing clinical burden with substantial impairment of daily 
activities and health-related quality of life (HRQoL) [2–
4]. Patients with severe disease (factor IX level ≤ 1% IU/
dL; FIX) experience frequent spontaneous and recurrent 
joint bleeds that, without appropriate treatment, lead 
to early arthritis, deformity, and other long-term com-
plications [5–7]. The burden of haemophilia B remains 
substantial and persistent [8–11]. Improved outcomes 
also come with an inherent treatment burden, as treat-
ments are administered 2–3 times per week for standard 
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half-life (SHL) FIX or, more recently, every 1–2 weeks for 
extended half-life (EHL) FIX [12, 13].
Haemophilia B and its treatment also bear a notable 
economic burden on patients and society [14–17]. The 
original CHESS study (known as CHESS I, “Cost of Hae-
mophilia in Europe: a Socioeconomic Survey”) reported 
significant costs associated with severe haemophilia and 
its treatment, including reduced employment and lost 
wages among patients and their caregivers in Europe 
[18]. Since the data collection period of CHESS I in 
2014–2015, haemophilia management and treatments 
have continued to evolve with the introduction and 
adoption of EHL and non-factor products into clinical 
practice. The CHESS II study, conducted in 2019–2020, 
sought to describe the comprehensive burden of hae-
mophilia in Europe following these advances, including 
capturing real-world use of EHL treatment and up-to-
date haemophilia care management practices. The holis-
tic burden of haemophilia B among patients with severe 
disease, in particular, has been underserved in the litera-
ture. As these patients are likely to receive prophylactic 
therapy, we focused this analysis on patients with severe 
haemophilia B receiving prophylaxis. The development 
of inhibitors is also a rightful area for attention in the lit-
erature, and in keeping with our objective to address less 
developed areas of research, historically, we focused on 
patients without inhibitors for this analysis.
Here, we analyzed data from the recent CHESS II study 
to provide updated real-world findings on management 
practices, disease burden, and unmet needs of adults 
with severe haemophilia B receiving FIX prophylaxis in 
Europe.
Results
A total of 132 CHESS II participants had severe hae-
mophilia B, of whom 75 (57%) were on continuous FIX 
prophylaxis and were included in the analysis. Patient-
reported data were available from 40 (53%) participants. 
The mean age was 36.2  years. Slightly fewer than half 
of the patients were receiving EHL prophylaxis (n = 33, 
44%; Table 1). Overall, most patients 76% were receiving 
primary prophylaxis; mean (SD) duration of secondary 
prophylaxis was 4.5 (3.87) years. There was broad geo-
graphic distribution of patients with the United Kingdom 
contributing the highest proportion (29%), followed by 
Italy (23%) and Spain (20%). Demographic characteristics 
were generally similar between patients receiving SHL or 
EHL prophylaxis.
Most patients with severe haemophilia B on FIX 
prophylaxis had ≥ 2 bleeding events per year (70%) and 
the mean ABR was 2.4 (Table 2). Mean number of bleed-
related hospitalisations overall was 0.67, and appeared 
lower among patients receiving EHL prophylaxis. 
Twenty-three percent of patients had ≥ 1 target joint and 
40% had ≥ 1 problem joint. ABR was similar between 
patients receiving EHL or SHL prophylaxis. History of 
joint surgery was similar between patients receiving EHL 
prophylaxis (33%) or SHL (24%), likewise for problem 
joints, but a greater proportion of patients receiving EHL 
reported target joints (Table 2).
Humanistic outcomes
The majority of patients reported mild or moderate 
chronic pain (76%), 5% reported severe chronic pain, 
and 19% reported no chronic pain. Most patients (63%) 
reported an impact of haemophilia on their daily lives 
and 20% reported adapting their treatment regimen in 
anticipation of physical activity. The overall mean EQ-5D 
score was 0.67 (standard deviation [SD], 0.21; Table  3). 
Due to small sample sizes, data are not reported sepa-
rately for the SHL and EHL subgroups.
Economic outcomes
The mean (SD) annual total haemophilia-related direct 
medical cost per patient was €235,723 (€154,953), com-
prised almost entirely of FIX treatment costs (€232,328; 
99%). Total annual FIX consumption was 245,175 IU, and 
Table 1 Baseline characteristics of patients with severe 
haemophilia B in CHESS II
EHL, extended half-life; FIX, Factor IX; HIV, human immunodeficiency virus; SD, 
standard deviation; SHL, short half-life







Age, mean (SD) 36.2 (15.97) 33.7 (14.26) 39.3 (17.66)
Weight, kg, mean (SD) 77.3 (11.07) 74.0 (11.58) 79.9 (10.06)
Country, n (%)
 UK 22 (29) 15 (36) 7 (21)
 Italy 17 (23) 11 (26) 6 (18)
 Spain 15 (20) 9 (21) 6 (18)
 France 11 (15) 4 (10) 7 (21)
 Germany 10 (13) 3 (7) 7 (21)
Medical history, n (%)
 Anxiety 9 (12) 5 (12) 4 (12)
 Depression 5 (7) 4 (10) 1 (3)
 HIV 1 (1) 0 1 (3)
 Hepatitis B 4 (5) 3 (7) 1 (3)
 Hepatitis C 9 (12) 4 (10) 5 (15)
FIX prophylaxis treatment, n (%)
 EHL 33 (44) – 33 (100)
 SHL 42 (56) 42 (100) –
Primary FIX prophylaxis, n (%) 57 (76) 29 (69) 28 (85)
Secondary FIX prophylaxis, n 
(%)
18 (24) 13 (31) 5 (15)
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was higher among SHL than EHL patients (286,969  IU 
and 191,983 IU, respectively; Fig. 1). FIX treatment costs 
varied substantially by country, with the highest observed 
among patients in Germany (€393,263) and the lowest 
from those in the United Kingdom (€182,219; Fig.  2). 
Mean (SD) annual haemophilia-related non-medical 
direct costs were €1,997 (€3,187), driven by state enti-
tlement payments (€1,082). Mean annual indirect costs 
were €8,973 (€15,398), driven by early retirement or work 
stoppage due to haemophilia (€5,389; Table 4).
Discussion
This analysis of the CHESS II real-world burden of ill-
ness study demonstrated the persistent negative impact 
of severe haemophilia B on patients in Europe. Patients 
averaged at least 2 bleeds per year, nearly half had at 
Table 2 Clinical outcomes from patients with severe haemophilia B on FIX prophylaxis in CHESS II (past 12 months)
EHL, extended half-life; SD, standard deviation; SHL, short half-life
† ABR data were incomplete/missing for 2 patients
‡ Types of surgery included arthrocentesis, arthrodesis, arthroplasty, arthroscopy, or synovectomy
# Bleed-related hospitalisation data were incomplete or missing for 13 patients






ABR, mean (SD)† 2.4 (1.67) 2.5 (2.62) 2.4 (2.14)
Number of bleeds per year, n (%)
 None 6 (15) 5 (15) 11 (15)
 1 6 (15) 5 (15) 11 (15)
 ≥ 2 28 (70) 23 (70) 51 (70)
History of joint surgery, n (%)‡ 10 (24) 11 (33) 21 (28)
Bleed-related hospitalisations, mean (SD)# 0.76 (0.95) 0.55 (1.30) 0.67 (1.10)
Bleed-related hospital days per patient, mean (SD) 1.2 (2.9) 1.9 (5.2) 1.5 (4.1)
Target joints, mean (SD) 0.3 (0.71) 0.4 (0.79) 0.4 (0.74)
Number of target joints, n (%) 35 (83) 23 (70) 58 (77)
None 3 (7) 8 (24) 11 (15)
 1 4 (10) 2 (6) 6 (8)
 ≥ 2
Problem joints, mean (SD) 0.6 (0.94) 0.9 (1.32) 0.7 (1.12)
Number of problem joints, n (%)
None 26 (62) 19 (58) 45 (60)
 1 8 (19) 6 (18) 14 (19)
 ≥ 2 8 (19) 8 (24) 16 (21)
Table 3 Humanistic outcomes from patients with severe haemophilia B utilising FIX prophylaxis in CHESS II
SD, standard deviation
Humanistic outcome reported by physicians All patients
(n = 75)
Chronic pain, n (%)




Patient-reported humanistic outcomes All patients
(n = 40)
Haemophilia impact on daily life, n (%) 25 (63)
Adapt treatment/physical activity, n (%) 8 (20)
EQ-5D score, mean (SD) 0.67 (0.21)
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least 1 problem joint, and the majority reported mild 
or moderate chronic pain. Mean HRQoL was low for 
patients undergoing FIX prophylaxis, and indirect costs 
from early retirement/work stoppage and reduced work 
productivity for both patients and their caregivers were 
substantial. The direct costs associated with severe hae-
mophilia B were substantial, driven almost entirely by 
FIX treatment.
This analysis of the recent CHESS II study provides a 
European perspective on real-world outcomes associated 
with FIX prophylaxis in patients with severe haemo-
philia B in the EU5. The study included a broad sample 
of patients receiving EHL or SHL treatment that was 
not limited to a single-center or a single-country analy-
sis. These findings were even consistent with unmet 
needs reported prior to widespread use of EHL therapy 
for severe haemophilia B in Europe. Berntorp and col-
leagues reported real-world outcomes from haemo-
philia registries across 7 European countries where 57% 
of haemophilia B patients had severe disease (also 57% 
Fig. 1 Mean annual FIX treatment consumption and direct medical costs. EHL, extended half-life; IU, international units; SHL, short half-life
Fig. 2 FIX treatment utilisation and costs by country. EHL, extended half-life; IU, international units; SHL, short half-life
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in CHESS II) [19]. Among patients with evaluable data 
for annual bleeds, Berntorp reported ≥ 1 bleed per year 
in 78% (57/73) of patients with severe haemophilia B 
(83% in CHESS II, 62/75) [19]. Other reports of the real-
world clinical burden of severe haemophilia B in Europe 
included CHESS I, the predecessor of the current study 
[18, 20]. In this study, we observed a nearly identical dis-
tribution of ABR between patients receiving SHL or EHL 
treatment, but a greater proportion of EHL than SHL 
patients had at least one target joint (30% vs 17%, respec-
tively). Physicians may have been more likely to prescribe 
EHL for their patients considered to have more severe 
joint complications, since switching to an EHL FIX prod-
uct has been suggested to improve joint health outcomes 
[21], which has been discussed in the literature anecdo-
tally but not quantified as of this writing [22, 23].
To our knowledge, CHESS II is the first multi-center 
study of EHL treatment use and costs among patients 
with severe haemophilia in the EU-5, specifically those 
with haemophilia B in this analysis. Though many 
patients had shifted to more expensive EHL therapy in 
CHESS II, the costs of haemophilia B in the EU5 were not 
substantially different from those observed with predom-
inantly SHL therapy in CHESS I. Mean annual haemo-
philia-related direct medical costs for any FIX treatment 
were €232,000 in CHESS II, nearly identical to those 
reported with SHL treatment in CHESS I (€230,000) 
[18]. This may be due to changes in FIX unit cost asso-
ciated with national tendering in EU, which varies with 
each country’s prioritization of prophylactic treatment 
in terms of both health policies and subsequent procure-
ment. The proportional distribution of SHL and EHL 
treatment utilisation varied across countries in CHESS II, 
as did mean annual direct medical costs, which was likely 
due to differences in health system structures, policies, 
and reimbursement rates and was consistent with find-
ings from CHESS I. The greatest proportion of EHL use 
and highest total costs were observed in Germany, which 
also showed the highest costs in the CHESS I analysis 
[18]. In general, we observed countries with lower pro-
portions of EHL use to have lower total factor IX treat-
ment costs, with the exception of Italy. This may have 
been due to health policies and/or procurement prac-
tices related to factor IX and EHL use specifically in this 
population.
Patients with severe haemophilia B in the CHESS II 
study showed substantial humanistic burden of disease 
and indirect costs despite FIX treatment. The majority 
of patients reported mild or moderate pain (76%) and 
impact of haemophilia on daily life (63%), consistent with 
published reports, particularly for patients with moderate 
to severe disease [4, 24]. The overall mean EQ-5D score 
among CHESS II patients with severe disease (mean 
0.67) was slightly lower than that reported from severe 
haemophilia B patients in CHESS I (mean 0.76) [25]. 
This may be reflective of a persistent unmet need over 
time. We did not examine EQ-5D results by age due to 
the sample size of patients with severe disease; however, 
the mean overall EQ-5D score of 0.67 was substantially 
lower than published population norms for the partici-
pating countries (ranging from 0.86–0.92) [26]. The indi-
rect costs of severe disease were observed to be similarly 
meaningful, comprised largely of early work stoppage or 
retirement (60%) followed by reduced productivity for 
caregivers (24%). The cost of lost productivity for patients 
was likely the smallest component of total indirect costs 
because early withdrawal from the workforce was the 
largest component, where severe haemophilia B may be 
more likely to keep working-age patients from working at 
Table 4 Mean annual indirect costs
EHL, extended half-life; SHL, short half-life
Note: Sample sizes for country-level costs for each outcome were too small to be 







Total indirect costs €11,907 €4083 €8973
 Germany – – €2447
 Spain – – €16,001
 France – – €36,809
 Italy – – €4340




 Germany – – €2447
 Spain – – €16,001
 France – – €36,809
 Italy – – €4340
 UK – – €3552
Patient lost productivity €1619 €1158 €1446
 Germany – – €2447
 Spain – – €426
 France – – €0
 Italy – – €654
 UK – – €3552
Caregiver lost productivity €2773 €1079 €2138
 Germany – – €0
 Spain – – €6345
 France – – €0
 Italy – – €851
 UK – – €0
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all (mean age, 36 years in this cohort), rather than result-
ing primarily in absenteeism and presenteeism. Compro-
mised employment due to severe haemophilia has been 
well established. Cutter and colleagues (2017) reported 
a negative impact of mild to severe haemophilia B on 
employment in the US as high as 95% among patients 
and 84–89% among caregivers and partners [27]. Patients 
who had left the workforce prematurely cited financial 
issues (59%), including healthcare expenses, and haemo-
philia-related issues (55%) most often.
Our analysis should be considered in the context of 
its strengths and limitations. The CHESS II study brings 
patient-reported outcomes and medical chart-extracted 
details to elucidate real-world encounters for patients 
with haemophilia B and is beholden to the expected limi-
tations of any retrospective cross-sectional study, such 
as the potential for selection bias, recall bias, and data 
extraction errors. For example, patients who had sought 
physician care due to bleeding or joint health issues in 
the past 12 months were more likely to be included in the 
sample. The small sample sizes of patients with SHL or 
EHL prophylaxis precluded comparisons between these 
treatment groups, particularly for country-level and 
patient-reported outcomes. This analysis of the CHESS II 
data set focused on patients with severe haemophilia B 
without inhibitors with a record of consistent FIX proph-
ylaxis over the past year. As such, our findings are not 
generalisable to patients with mild or moderate disease, 
those with inhibitors, and/or those receiving on-demand 
or less consistent prophylaxis therapy. Unmeasured vari-
ables may also impact the generalisability of our findings 
to other patient populations. Patient-reported outcomes 
(humanistic burden, indirect costs, and direct non-med-
ical costs) were available from a subset of the overall 
study cohort (40/75 patients), which may have reflected 
a selection bias specific to those willing to complete the 
patient questionnaire. Our findings were from 5 large 
European countries, whereas recent studies of EHL costs 
across haemophilia types and subgroups have tended to 
be single-center, single-country, or more tightly focused 
regional analyses [28, 29].
Conclusions
These findings from an analysis of the CHESS II study 
demonstrate the substantial clinical and humanistic bur-
den of severe haemophilia B, together with a consistent 
economic burden. Our analysis provides a comprehen-
sive assessment of real-world outcomes among patients 
receiving SHL and EHL FIX prophylaxis in Europe cur-
rently, highlighting the persistent unmet needs for these 
patients, their caregivers, and society.
Methods
Study design and patients
CHESS II is a retrospective burden of illness study of 
European adults with haemophilia that utilises a similar 
design and methodology as the original CHESS study, 
described elsewhere [18]. Briefly, CHESS II is a cross-
sectional study of male adults (≥ 18 years old) with mild, 
moderate, or severe haemophilia A or B from eight Euro-
pean countries (Denmark, France, Germany, Italy, the 
Netherlands, Romania, Spain and the United Kingdom); 
however, sufficient data were only available from five 
countries (France, Germany, Italy, Spain and the United 
Kingdom) for this analysis. Patients and their haemo-
philia-treating physicians each completed questionnaires 
collecting information on self-reported health status, 
non-medical costs, and work impairment (from patients) 
and on the patient’s medical history (from the physicians) 
over the previous 12  months. Participating physicians 
recruited consecutive patients with haemophilia regard-
less of the reason for the clinical consultation visit. All 
data were collected between 2019 and 2020. The present 
analysis focused on patients with severe haemophilia B 
without a current inhibitor to FIX who received continu-
ous EHL or SHL FIX prophylaxis in France, Germany, 
Italy, Spain and the United Kingdom.
The CHESS II study was approved by the Research Eth-
ics Sub Committee of the Faculty of Health and Social 
care within the University of Chester and conducted in 
correspondence with regional and relevant guidelines. 
Patient consent for use of clinical data was not required 
as per European Pharmaceutical Market Research Asso-
ciation (EPhMRA) guidelines. Patient consent was 
obtained via tick box selection for the patient-reported 
element of the study.
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Study outcomes and analysis
In addition to demographic and clinical characteristics, 
we analyzed patient- and physician-reported clinical, 
humanistic, and economic outcomes from CHESS II. 
Clinical and economic outcomes were reported by the 
physicians based on review of the medical chart. A sub-
set of patients reported humanistic outcomes including 
quality of life measures, with the exception of chronic 
pain which was reported by the physician. Demo-
graphic characteristics were collated from both patient- 
and physician-reported information. Clinical outcomes 
included frequency of bleeding events, annualised 
bleeding rate (ABR), bleed-related hospitalisations, tar-
get joints, problem joints, and joint surgery. The defi-
nition of a target joint was based on the International 
Society on Thrombosis and Haemostasis (ISTH) defi-
nition (“three or more spontaneous bleeds into a sin-
gle joint within a consecutive 6-month period. Where 
there have been ≤ 2 bleeds into the joint within a con-
secutive 12-month period the joint is no longer consid-
ered a target joint”) [30]. A problem joint was defined 
as “any joint that has been permanently damaged as a 
result of a bleeding disorder, with or without persistent 
bleeding, and may involve chronic pain and/or limited 
range of movement due to compromised joint integrity 
such as chronic synovitis and/or hemophilic arthropa-
thy” [31].
Humanistic outcomes included chronic pain, impact 
of haemophilia on daily life, adaptation of treatment 
regimen in anticipation of physical activity, and HRQoL 
based on responses to the EuroQoL 5-Dimension 
5-Level (EQ-5D). Patients reported chronic pain over 
the previous 12  months on a scale of 0–10 (0 for “no 
pain,” 10 for “extreme pain”). Patient-reported work 
productivity impact was collected using the Work Pro-
ductivity and Activity Impairment (WPAI) instrument 
(Reilly Associates, www. reill yasso ciates. net/ wpai_ gener 
al. html). Physicians reported FIX usage (IU) for each 
patient over the previous 12 months.
Economic outcomes included haemophilia-related 
direct medical costs, direct non-medical costs, and 
indirect and societal costs. Direct medical costs 
included medications (including over-the-counter 
medications), hospitalisations, physician consultations, 
professional caregiving assistance, medical devices, 
surgical interventions, and tests and procedures used 
for diagnosis and follow-up of haemophilia. Direct 
medical costs were calculated for each country, apply-
ing country-specific unit costs for each type of quali-
fying medical encounter extracted from the patient’s 
medical chart (Appendix Table 5). Direct non-medical 
costs included those for alternative therapies, home 
equipment and/or adaptations, transportation and 
transfer payments (including state benefits or disabil-
ity allowances). Indirect costs included loss of wages 
and productivity due to absenteeism or impairment 
while at work both for patients and their informal car-
egivers, using the country-specific average salaries as a 
proxy for the opportunity costs. Components of each 
cost outcome and country-specific unit cost sources are 
provided in Appendix Table 6. Factor IX unit costs for 
each country are provided in Table 7.
All patient characteristics and outcomes were summa-
rised using descriptive statistics, as means with standard 
deviations for continuous variables and as number and 
proportion of patients for categorical variables. All analy-
ses were conducted using Stata 16.
Appendix
See Tables 5, 6 and 7.
Table 5 Country-specific direct medical unit cost sources
Country Unit cost data source(s)
France L’Assurance Maladie, https:// www. ameli. fr
Ministère des Solidarités et de la Santé, https:// solid arites- sante. gouv. fr
ViDAL, https:// www. vidal. fr
Germany Kassenärztliche Bundesvereinigung and Einheitlicher Bewertungsmaßstab, https:// www. kbv. de/ html/ index. php
Mein Pharmaversand, http:// meinp harma versa nd. de
Rote-Liste Service, https:// www. rote- liste. de
Italy Ministero della Salute, https:// www. trova norme. salute. gov. it
Tariffa minima degli onorari per le prestazioni medico-chirurgiche, https:// www. ordin emedi cilat ina. it/ files/ 521. pdf
Starbene, https:// www. starb ene. it
Spain Oblikue, http:// esalud. oblik ue. com
Agencia Española de Medicamentos y Productos Sanitarios, https:// www. aemps. gob. es
UK National Schedule of Reference Costs, https:// www. engla nd. nhs. uk/ natio nal- cost- colle ction/
The Electronic Medicines Compendium, https:// www. medic ines. org. uk/ emc# gref
The NICE British National Formulary, https:// www. nice. org. uk/ bnf- uk- only
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Table 6 Cost components used in the CHESS II study
Outcome Component category Measured element
Direct medical costs Hospitalisations Day case
Outpatient (ie, for planned treatments)
Inpatient, including length of stay
Surgical procedures Number and type of surgeries
Length of stay
Time spent in intensive care
Consultant visits Haematologist
Other specialties
Tests and examinations Blood tests
Other tests and examinations
Coagulation factor Brand (current and previous)
Dosage
Frequency
Professional caregiver Hourly wage
Hours per week




Requirement for aids/equipment Walking aids
Home adjustments
Transfer payments Entitlement per month
Indirect costs Work productivity impact Absenteeism
Early retirement/stopped working
Caregiver burden Hours per week
Work productivity impact for caregiver
Table 7 Factor IX unit costs (2021 unit costs unless noted 
otherwise)a
Unit costs were from the Pharmaceutical Pricing and Reimbursement 
Information (https:// ppri. goeg. at/ medic ine_ price_ data)
a Other country-specific sources were as follows: for the United Kingdom, the 
British National Formulary (https:// www. nice. org. uk/) and Branded Health 
Service Medicines Regulations 2018 (https:// www. legis lation. gov. uk/ uksi/ 2018/ 
345/ conte nts/ made); France, Modalités de prise en charge d’Aprolix (https:// 
www. hemat oalau ne. fr/ rubri ques/ vie- des- medic aments/ modal ites- de- prise- 
charge- dalpr olix- eftre nonac og- alpha/#), Légifrance (https:// www. legif rance. 
gouv. fr); Italy, Starbene (www. starb ene. it); Spain, La Comisión Interministerial 
modifica el precio de 50 medicamentos (https:// www. actas anita ria. com/ la- 
comis ion- inter minis terial- modifi ca- el- precio- de- 50- medic ament os/#: ~: text= 
En% 20cua nto% 20al% 20Alp rolix% 2C% 20con ,€% 20para% 20el% 203000% 20Ul)
FIX unit cost 
(EUR)
UK France Germany Italy Spain
Alprolix® – 0.96 (2018)a 1.47 1.38 1.24 (2020)a
Idelvion® 2.32 – 1.97 2.20 2.30 (2020)a
Refixia® 2.71 – 1.70 – –
BeneFIX® 0.67a 0.65 (2011)a 0.87 0.73a 0.46
Rixubis® 0.67 0.65 (2017)a 0.77 0.69 0.46
AlphaNine® 0.43 (2018)a – 0.72 0.41a –
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correspondence with regional and relevant guidelines, in partnership with the 
National Hemophilia Foundation (NHF) in the United States. Consultative discus-
sions regarding research design were held with the NHF to ensure relevance 
and adequacy of the research questions, objectives and methods. Patient 
consent for use of clinical data was not required (as per European Pharmaceuti-
cal Market Research Association (EPhMRA) guidelines). Patient consent was 
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